LLY
Eli Lilly and Company
LLY has the edge over RCUS overall, supported by stronger fundamentals and lower modeled downside.
RCUS
Arcus Biosciences, Inc.
RCUS trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RCUS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
RCUS's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RCUS PE Valuation
RCUS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RCUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RCUS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RCUS on earnings quality, reporting a profit while its opponent remains loss making.
RCUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.62 | -$0.18 |
| Q2 2026 | -$3.89 | -$0.72 |
| Q1 2026 | -$3.17 | +$1.02 |
| Q4 2025 | -$3.29 | -$0.19 |
| Q3 2025 | -$3.44 | -$0.29 |
| Q2 2025 | -$3.17 | -$0.08 |
| Q1 2025 | -$4.19 | -$1.08 |
| Q4 2024 | -$3.10 | +$1.05 |
RCUS lost $3.62 per share over the past year, about the same as its loss the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RCUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RCUS on profitability, with a higher operating margin.
RCUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9M | -65% |
| Q2 2026 | $41M | -74% |
| Q1 2026 | $17M | -39% |
| Q4 2025 | $33M | +27% |
| Q3 2025 | $26M | -46% |
| Q2 2025 | $160M | +310% |
| Q1 2025 | $28M | -81% |
| Q4 2024 | $26M | -16% |
RCUS's revenue has slid since its 2021 peak: $9M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1456% | -909 points |
| Q2 2026 | -234% | -229 points |
| Q1 2026 | -788% | -353 points |
| Q4 2025 | -345% | +51 points |
| Q3 2025 | -546% | -327 points |
| Q2 2025 | -5% | +267 points |
| Q1 2025 | -436% | -425 points |
| Q4 2024 | -396% | -103 points |
RCUS's operating margin was −1456% last quarter, down 909 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RCUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
RCUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | +$9M |
| Q2 2026 | -$119M | +$14M |
| Q1 2026 | -$138M | -$5M |
| Q4 2025 | -$121M | -$20M |
| Q3 2025 | -$97M | -488% |
| Q2 2025 | -$133M | -$39M |
| Q1 2025 | -$133M | -$127M |
| Q4 2024 | -$101M | -$7M |
RCUS has burned cash in almost every quarter: −$466M over the past year, against −$464M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RCUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RCUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1.3M shares |
| 1 year | +20% | +20.9M shares |
| 3 years | +71% | +52.8M shares |
| 5 years | +82% | +57.3M shares |
| Available history | +189% | +83.3M shares |
RCUS has 127M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RCUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -2.7x | Net Cash |
| Q2 2022 | -3.8x | Net Cash |
| Q1 2022 | -8.5x | Net Cash |
| Q4 2021 | -2.6x | Net Cash |
RCUS has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RCUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.2 | Neutral |
| Stochastic | 4.6 | Oversold |
RCUS's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RCUS PE vs Healthcare Sector
| Metric | RCUS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RCUS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RCUS on trend strength, trading above more of its moving averages.
RCUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.1 | 16% below |
| 20 week MA | $25.5 | 30% below |
| 50 week MA | $23.9 | 26% below |
| 100 week MA | $18.0 | 1.1% below |
| 200 week MA | $17.8 | 0.1% above |
RCUS has fallen below most of its moving averages, though it's still 0.1% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RCUS on returns for 2026, with the stronger performance.
RCUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $30.6 | +187% |
| 2021 | $30.6 | $44.6 | +46% |
| 2022 | $44.6 | $20.4 | -54% |
| 2023 | $20.4 | $19.1 | -6.4% |
| 2024 | $19.1 | $15.3 | -20% |
| 2025 | $15.3 | $23.1 | +51% |
| 2026 YTD | $23.1 | $17.8 | -23% |
RCUS's yearly returns have swung widely, from +187% in 2020 to −54% in 2022. It's down 23% so far in 2026.